Valuation : Orexo AB

Market Cap 548M 57.16M 49.3M 46.38M 42.25M 79.45M 5.42B 79.88M 213M 2.76B 215M 210M 9.15B P/E 2026 *
-1.5x
P/E 2027 * -2.16x
Enterprise Value 443M 46.21M 39.86M 37.5M 34.16M 64.24M 4.39B 64.58M 173M 2.23B 173M 170M 7.4B EV / Sales 2026 *
23.3x
EV / Sales 2027 * 15x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-4.08%
1 week+11.23%
Current month-4.08%
1 month+4.01%
3 months-25.07%
6 months-43.81%
Current year-49.97%
1 week 13
Extreme 13
16.6
1 month 12.9
Extreme 12.9
16.6
Current year 12.9
Extreme 12.9
36
1 year 12.9
Extreme 12.9
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-4.08%+11.23%-28.79%-15.39% 57.23M
+0.88%-4.92%+74.01%+35.42% 365B
+0.54%+0.29%+28.56%-16.22% 70.19B
+1.20%-1.93%+46.18%+150.37% 12.09B
+2.25%+4.19%+5.58%+0.62% 8.61B
+1.95%+3.01%-9.74%+3.85% 4.99B
-1.19%-1.90%-27.14%+19.28% 4.56B
-1.70%+2.25%-29.79%+0.38% 3.16B
-0.69%-3.13%-1.35%+35.24% 2.57B
+0.65%-0.03%-17.43%-16.02% 2.03B
Average -0.04%+0.32%+4.01%+19.75% 47.28B
Weighted average by Cap. +0.82%-2.17%+61.94%+29.11%

Financials

2026 *2027 *
Net sales 19M 1.98M 1.71M 1.61M 1.46M 2.75M 188M 2.77M 7.4M 95.62M 7.44M 7.28M 317M 27M 2.81M 2.43M 2.28M 2.08M 3.91M 267M 3.93M 10.51M 136M 10.57M 10.34M 451M
Net income -375M -39.09M -33.72M -31.72M -28.9M -54.34M -3.71B -54.64M -146M -1.89B -147M -144M -6.26B -270M -28.2M -24.32M -22.88M -20.85M -39.2M -2.68B -39.41M -105M -1.36B -106M -104M -4.51B
Net Debt -105M -10.95M -9.44M -8.88M -8.09M -15.22M -1.04B -15.3M -40.87M -528M -41.1M -40.21M -1.75B -143M -14.91M -12.86M -12.1M -11.02M -20.72M -1.41B -20.83M -55.66M -720M -55.97M -54.76M -2.39B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
26-09-01 SEK 15.06 -4.08% 154,190
26-08-31 SEK 15.70 +17.34% 163,007
26-08-28 SEK 13.38 +2.14% 30,738
26-08-27 SEK 13.10 -1.21% 43,736
26-08-26 SEK 13.26 -2.07% 29,433
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise